Antonio Henriques
@antoniohenriques.bsky.social
Founder & CEO of Momentum Therapeutics
Developing drugs for neurodegeneration and aging
Ex-Genentech, Amgen, Sanofi | Boston
Developing drugs for neurodegeneration and aging
Ex-Genentech, Amgen, Sanofi | Boston
Reposted by Antonio Henriques
"Amid all the warnings about a ‘dementia tsunami’, here are the things you should know.
When we dig into new research we see why all the alarming headlines are written, but also that science is bringing new hope."
🧪🧠 #neuroskyence
www.theguardian.com/commentisfre...
When we dig into new research we see why all the alarming headlines are written, but also that science is bringing new hope."
🧪🧠 #neuroskyence
www.theguardian.com/commentisfre...
Amid all the warnings about a ‘dementia tsunami’, here are the things you should know | Devi Sridhar
When we dig into new research we see why all the alarming headlines are written, but also that science is bringing new hope, says Devi Sridhar, chair of global public health at the University of Edinb...
www.theguardian.com
April 8, 2025 at 10:12 AM
"Amid all the warnings about a ‘dementia tsunami’, here are the things you should know.
When we dig into new research we see why all the alarming headlines are written, but also that science is bringing new hope."
🧪🧠 #neuroskyence
www.theguardian.com/commentisfre...
When we dig into new research we see why all the alarming headlines are written, but also that science is bringing new hope."
🧪🧠 #neuroskyence
www.theguardian.com/commentisfre...
God, it's brutal out here
April 6, 2025 at 8:06 PM
God, it's brutal out here
No better way to kick off this next chapter than spending my first full day in Boston—after 8 years in California—at the MassBio conference. Grateful for the warm welcome and excited for what’s ahead.
March 26, 2025 at 6:16 PM
No better way to kick off this next chapter than spending my first full day in Boston—after 8 years in California—at the MassBio conference. Grateful for the warm welcome and excited for what’s ahead.
Reposted by Antonio Henriques
Interleukin-12 signaling drives Alzheimer’s disease pathology through disrupting neuronal and oligodendrocyte homeostasis www.nature.com/articles/s43...
Interleukin-12 signaling drives Alzheimer’s disease pathology through disrupting neuronal and oligodendrocyte homeostasis - Nature Aging
Schneeberger, Kim, Geesdorf, Rajewsky, Heppner et al. tease IL-12 and IL-23 signaling apart in mouse models and human brain tissue to define a role for oligodendroglial and neuronal IL-12 signaling in...
www.nature.com
March 14, 2025 at 10:00 AM
Interleukin-12 signaling drives Alzheimer’s disease pathology through disrupting neuronal and oligodendrocyte homeostasis www.nature.com/articles/s43...
Regardless of how unfair it is that these projects receive funding while therapeutics do not, these mice are ridiculously cute
The de-extinction company Colossal Biosciences wants to bring back the mammoth, and it’s starting with a woolly mouse.
Read more here: buff.ly/xKPLn1c
Read more here: buff.ly/xKPLn1c
March 5, 2025 at 11:33 AM
Regardless of how unfair it is that these projects receive funding while therapeutics do not, these mice are ridiculously cute
Watching Severance and interpreting it as a TV show about an intricate clinical trial design makes it even more mind-blowing
March 2, 2025 at 11:40 AM
Watching Severance and interpreting it as a TV show about an intricate clinical trial design makes it even more mind-blowing
Governments should aim to become leaner—when it’s feasible to do more with less. But shedding weight at record speed by cutting off both arms and legs isn’t exactly a winning long-term strategy
February 10, 2025 at 1:44 AM
Governments should aim to become leaner—when it’s feasible to do more with less. But shedding weight at record speed by cutting off both arms and legs isn’t exactly a winning long-term strategy
Feels like Christmas morning—can’t wait to read this one!
@charlespiller.bsky.social
@charlespiller.bsky.social
February 8, 2025 at 6:14 PM
Feels like Christmas morning—can’t wait to read this one!
@charlespiller.bsky.social
@charlespiller.bsky.social
Why limit yourself to developing neurodegenerative therapies when you can also create art?
With a cofounder who’s both a scientist and an artist, the possibilities are endless 👨🏻🔬👨🏻🎨
With a cofounder who’s both a scientist and an artist, the possibilities are endless 👨🏻🔬👨🏻🎨
February 6, 2025 at 7:29 PM
Why limit yourself to developing neurodegenerative therapies when you can also create art?
With a cofounder who’s both a scientist and an artist, the possibilities are endless 👨🏻🔬👨🏻🎨
With a cofounder who’s both a scientist and an artist, the possibilities are endless 👨🏻🔬👨🏻🎨
Excited to share that I'll be attending the Global Healthspan Summit 2025 as Momentum Therapeutics continues advancing our mission to develop novel therapies that protect the nervous system and combat aging.
If you'll be there, let’s connect!
#Hevolution #Healthspan #GHS2025
If you'll be there, let’s connect!
#Hevolution #Healthspan #GHS2025
February 2, 2025 at 10:30 AM
Excited to share that I'll be attending the Global Healthspan Summit 2025 as Momentum Therapeutics continues advancing our mission to develop novel therapies that protect the nervous system and combat aging.
If you'll be there, let’s connect!
#Hevolution #Healthspan #GHS2025
If you'll be there, let’s connect!
#Hevolution #Healthspan #GHS2025
Reposted by Antonio Henriques
We knew about the potential origin of Parkinson's disease from the gut (known as Braak’s hypothesis). But the kidney?!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease - Nature Neuroscience
Yuan et al. find that the kidney can serve as a site of initiation for the spread of pathological α-synuclein to the brain, contributing to the development of Parkinson’s disease (PD) and providing a ...
www.nature.com
January 23, 2025 at 3:13 PM
We knew about the potential origin of Parkinson's disease from the gut (known as Braak’s hypothesis). But the kidney?!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
This is the mantra.
Insitro’s CEO Daphne Koller for Endpoints:
Insitro’s CEO Daphne Koller for Endpoints:
December 20, 2024 at 1:47 PM
This is the mantra.
Insitro’s CEO Daphne Koller for Endpoints:
Insitro’s CEO Daphne Koller for Endpoints:
Reposted by Antonio Henriques
A neurologist with 2 APOE4 copies tells us about his experience with #Alzheimers disease
washingtonpost.com/wellness/202...
washingtonpost.com/wellness/202...
December 17, 2024 at 3:32 PM
A neurologist with 2 APOE4 copies tells us about his experience with #Alzheimers disease
washingtonpost.com/wellness/202...
washingtonpost.com/wellness/202...
Argentina is the only country in South America with Nobel Prizes in scientific categories, and has made significant contributions to global science, particularly in biochemistry and medicine.
December 12, 2024 at 3:10 PM
Argentina is the only country in South America with Nobel Prizes in scientific categories, and has made significant contributions to global science, particularly in biochemistry and medicine.
Reposted by Antonio Henriques
it's big, and it's a review of 601 papers on the topic - but here's an update on Neuroinflammation in Alzheimer's Disease
www.nature.com/articles/s41...
led by Michael Heneka, published in @natrevimmunol.bsky.social today
(MANY more authors listed and linked below)
www.nature.com/articles/s41...
led by Michael Heneka, published in @natrevimmunol.bsky.social today
(MANY more authors listed and linked below)
Neuroinflammation in Alzheimer disease - Nature Reviews Immunology
This Review provides an in-depth examination of how inflammation contributes to neurodegeneration in Alzheimer disease. The authors explore the impact of extrinsic factors, such as brain trauma, diet ...
www.nature.com
December 10, 2024 at 3:03 AM
it's big, and it's a review of 601 papers on the topic - but here's an update on Neuroinflammation in Alzheimer's Disease
www.nature.com/articles/s41...
led by Michael Heneka, published in @natrevimmunol.bsky.social today
(MANY more authors listed and linked below)
www.nature.com/articles/s41...
led by Michael Heneka, published in @natrevimmunol.bsky.social today
(MANY more authors listed and linked below)
Brain delivery has the potential to transform patient care - and it could become a reality soon. This snapshot of transcytosis strategies (from GS) highlights how neurobiotech is on the verge of revolutionizing treatments for CNS diseases. I only wish Montara had been included in the discussion.
December 1, 2024 at 3:46 PM
Brain delivery has the potential to transform patient care - and it could become a reality soon. This snapshot of transcytosis strategies (from GS) highlights how neurobiotech is on the verge of revolutionizing treatments for CNS diseases. I only wish Montara had been included in the discussion.
A sincere and shameless plug: This Thanksgiving, I’m especially grateful for my healthy axons.
Photo Credit: Felipe Court, our Chief Scientific Officer.
Photo Credit: Felipe Court, our Chief Scientific Officer.
November 29, 2024 at 1:51 PM
A sincere and shameless plug: This Thanksgiving, I’m especially grateful for my healthy axons.
Photo Credit: Felipe Court, our Chief Scientific Officer.
Photo Credit: Felipe Court, our Chief Scientific Officer.
Reposted by Antonio Henriques
My advice to graduates of my class who still (!) insist on going into #biotech investment banking
First, a few tips re science/medical data:
First, a few tips re science/medical data:
November 24, 2024 at 2:45 PM
My advice to graduates of my class who still (!) insist on going into #biotech investment banking
First, a few tips re science/medical data:
First, a few tips re science/medical data:
Neuroscience and obesity continue to stand out as the dominant and perhaps only major headwinds driving biopharma business development this year, consistently delivering impressive deals and partnerships.
Novartis acquires Astellas-partnered Kate Therapeutics, a neuromuscular gene therapy startup, for up to $1.1 billion
Follows MorphoSys, Mariana acquisitions earlier this years, with more hunger for additional bolt-on deals
Follows MorphoSys, Mariana acquisitions earlier this years, with more hunger for additional bolt-on deals
Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B
Novartis is acquiring Kate Therapeutics for $1.1 billion, focusing on gene therapy and neuroscience. CEO Vas Narasimhan and CFO Harry Kirsch indicate future M&A deals will likely stay under $3 billion...
endpts.com
November 21, 2024 at 5:49 PM
Neuroscience and obesity continue to stand out as the dominant and perhaps only major headwinds driving biopharma business development this year, consistently delivering impressive deals and partnerships.
Reposted by Antonio Henriques
November 20, 2024 at 1:27 PM
November 19, 2024 at 4:10 AM
Proud to be part of this movement alongside brilliant peers and friends shaping the future of innovation in biotech.
Cashing in on founder-led biotech
Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite cen.acs.org/business/sta... #chemsky
Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite cen.acs.org/business/sta... #chemsky
Founder-led biotech is gaining steam
Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite
cen.acs.org
November 15, 2024 at 4:40 PM
Proud to be part of this movement alongside brilliant peers and friends shaping the future of innovation in biotech.
November 12, 2024 at 5:38 PM